MedTrace Logo

The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients

NCT00696761 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2021-02-17

Study results available
· View outcomes & findings →

Summary

Benign prostatic hyperplasia (BPH) is a common condition among older men. The efficacy of α1-blockers for treating BPH has been well documented and they are recommended for the treatment of BPH by clinical guidelines.

It is not well known if a stratification based on the grade of BOO and bladder contractility has any predictive value for patients who are treated with an α1-selective blocking agent. In our study, we investigated possible differences in treatment outcome between patients with and without BOO, and with or without proper contractility who are treated with alfuzosin. So we will compare the quantified improvements 12 months after alfuzosin medication in LUTS/BPH patients by the grade of BOO and/or bladder contractility.

Conditions

  • BPH

Interventions

DRUG

Alfuzosin

10mg, once daily, 12months

DRUG

Alfuzosin

10mg, once daily, 12months

DRUG

Alfuzosin

10mg, once daily, 12months

DRUG

Alfuzosin

10mg, once daily, 12months

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Myung-Soo Choo, M.D., PhD · From the Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-07-31
Completion
2008-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00696761 on ClinicalTrials.gov